A Rare-Disease Approach to Seizure Treatment

The past decade has seen little by way of new treatment for epilepsy, and existing medications can come with significant adverse reactions. Given this, biopharmaceutical companies need to take a different course to improve treatments for people with seizure disorders. For many developers, taking a rare-disease approach may be the answer.

Back Bay Life Science Advisors examined how and why biopharmaceutical companies are focusing on smaller, underserved patient pools with high unmet need with the expectation that the broader epilepsy community may ultimately benefit.